JMJennifer L. Marshall

Jennifer L. Marshall

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jennifer L. Marshall has a total of 315 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases

    by Ilya Korsunsky, Kevin Wei, Mathilde Pohin, Edy Y. Kim, Francesca Barone, Joyce B. Kang, Matthias Friedrich, Jason Turner, Saba Nayar, Benjamin A. Fisher, et al.

    Summary: Pro-inflammatory fibroblasts are critical to pathogenesis in rheumatoid arthritis, inflammatory bowel disease, interstitial lung disease, and Sjögren’s syndrome, and represent a novel therapeutic target for chronic inflammatory disease. However, the heterogeneity of fibroblast phenotypes, exacerbated by the lack of a common cross-tissue taxonomy, has limited the understanding of which pathways are shared by multiple diseases. To investigate, we profiled patient-derived fibroblasts from inflamed and non-inflamed synovium, intestine, lung, and salivary glands with single-cell RNA-sequencing. We integrated all fibroblasts into a multi-tissue atlas to characterize shared and tissue-specific phenotypes. Two shared clusters, CXCL10 + CCL19 + immune-interacting and SPARC + COL3A1 + vascular-interacting fibroblasts were expanded in all inflamed tissues and additionally mapped to dermal analogues in a public atopic dermatitis atlas. We further confirmed these human pro-inflammatory fibroblasts in animal models of lung, joint, and intestinal inflammation. This work represents the first cross-tissue, single-cell fibroblast atlas revealing shared pathogenic activation states across four chronic inflammatory diseases.


  • Open Access

    Response to: ‘Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis’ by Cutolo et al

    by Susan Aungier, Alison J Cartwright, Anja Schwenzer, Jennifer Marshall, Mike R Dyson, Peter Slavny, Kothai Parthiban, Aneesh Karatt-Vellatt, Ilfita Sahbudin, Eric Culbert, et al.

    The authors would like to thank the Technology Hub Imaging Centre at the University of Birmingham.

  • Open Access

    Outer membrane protein size and LPS O-antigen define protective antibody targeting to the Salmonella surface

    by C. Coral Domínguez-Medina, Marisol Pérez-Toledo, Anna E. Schager, Jennifer L. Marshall, Charlotte N. Cook, Saeeda Bobat, Hyea Hwang, Byeong Jae Chun, Erin Logan, Jack A. Bryant, et al.

    Lipopolysaccharide (LPS) O-antigen (O-Ag) is known to limit antibody binding to surface antigens, although the relationship between antibody, O-Ag and other outer-membrane antigens is poorly understood. Here we report, immunization with the trimeric porin OmpD from Salmonella Typhimurium (STmOmpD) protects against infection. Atomistic molecular dynamics simulations indicate this is because OmpD trimers generate footprints within the O-Ag layer sufficiently sized for a single IgG Fab to access. While STmOmpD differs from its orthologue in S. Enteritidis (SEn) by a single amino-acid residue, immunization with STmOmpD confers minimal protection to SEn. This is due to the OmpD-O-Ag interplay restricting IgG binding, with the pairing of OmpD with its native O-Ag being essential for optimal protection after immunization. Thus, both the chemical and physical structure of O-Ag are key for the presentation of specific epitopes within proteinaceous surface-antigens. This enhances combinatorial antigenic diversity in Gram-negative bacteria, while reducing associated fitness costs.


  • Top Cited Papers

    Distinct fibroblast subsets drive inflammation and damage in arthritis

    by Adam P. Croft, Joana Campos, Kathrin Jansen, Jason D. Turner, Jennifer Marshall, Moustafa Attar, Loriane Savary, Corinna Wehmeyer, Amy J. Naylor, Samuel Kemble, et al.

    The identification of lymphocyte subsets with non-overlapping effector functions has been pivotal to the development of targeted therapies in immune-mediated inflammatory diseases (IMIDs)1,2. However, it remains unclear whether fibroblast subclasses with non-overlapping functions also exist and are responsible for the wide variety of tissue-driven processes observed in IMIDs, such as inflammation and damage3,4,5. Here we identify and describe the biology of distinct subsets of fibroblasts responsible for mediating either inflammation or tissue damage in arthritis. We show that deletion of fibroblast activation protein-α (FAPα)+ fibroblasts suppressed both inflammation and bone erosions in mouse models of resolving and persistent arthritis. Single-cell transcriptional analysis identified two distinct fibroblast subsets within the FAPα+ population: FAPα+THY1+ immune effector fibroblasts located in the synovial sub-lining, and FAPα+THY1− destructive fibroblasts restricted to the synovial lining layer. When adoptively transferred into the joint, FAPα+THY1− fibroblasts selectively mediate bone and cartilage damage with little effect on inflammation, whereas transfer of FAPα+ THY1+ fibroblasts resulted in a more severe and persistent inflammatory arthritis, with minimal effect on bone and cartilage. Our findings describing anatomically discrete, functionally distinct fibroblast subsets with non-overlapping functions have important implications for cell-based therapies aimed at modulating inflammation and tissue damage.


  • Open Access

    Aryl Hydrocarbon Receptor Interacting Protein Maintains Germinal Center B Cells through Suppression of BCL6 Degradation

    by Dijue Sun, Urszula Stopka-Farooqui, Sayka Barry, Ezra Aksoy, Gregory Parsonage, Anna Vossenkämper, Melania Capasso, Xinyu Wan, Sherine Norris, Jennifer L. Marshall, et al.


  • Open Access

    Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?

    by Susan R Aungier, Alison J Cartwright, Anja Schwenzer, Jennifer L Marshall, Michael R Dyson, Peter Slavny, Kothai Parthiban, Aneesh Karatt-Vellatt, Ilfita Sahbudin, Eric Culbert, et al.

    Objectives Controlled immune responses rely on integrated crosstalk between cells and their microenvironment. We investigated whether targeting proinflammatory signals from the extracellular matrix that persist during pathological inflammation provides a viable strategy to treat rheumatoid arthritis (RA). Methods Monoclonal antibodies recognising the fibrinogen-like globe (FBG) of tenascin-C were generated by phage display. Clones that neutralised FBG activation of toll-like receptor 4 (TLR4), without impacting pathogenic TLR4 activation, were epitope mapped by crystallography. Antibodies stained synovial biopsies of patients at different stages of RA development. Antibody efficacy in preventing RA synovial cell cytokine release, and in modulating collagen-induced arthritis in rats, was assessed. Results Tenascin-C is expressed early in the development of RA, even before disease diagnosis, with higher levels in the joints of people with synovitis who eventually developed RA than in people whose synovitis spontaneously resolved. Anti-FBG antibodies inhibited cytokine release by RA synovial cells and prevented disease progression and tissue destruction during collagen-induced arthritis. Conclusions Early changes in the synovial microenvironment contribute to RA progression; blocking proinflammatory signals from the matrix can ameliorate experimental arthritis. These data highlight a new drug class that could offer early, disease-specific immune modulation in RA, without engendering global immune suppression.


  • Open Access

    Podoplanin regulates the migration of mesenchymal stromal cells and their interaction with platelets

    by Lewis S. C. Ward, Lozan Sheriff, Jennifer L. Marshall, Julia E. Manning, Alexander Brill, Gerard B. Nash, Helen M. McGettrick

    Mesenchymal stromal cells (MSC) up-regulate podoplanin at sites of infection, chronic inflammation, and cancer. We investigated the functional consequences of podoplanin expression on the migratory potential of MSC and their interactions with circulating platelets. Expression of podoplanin significantly enhanced the migration of MSC compared to MSC lacking podoplanin. Rac-1 inhibition altered the membrane localisation of podoplanin and in turn significantly reduced MSC migration. Blocking Rac-1 activity had no effect on the migration of MSC lacking podoplanin, indicating it was responsible for regulation of migration through podoplanin. When podoplanin-expressing MSC were seeded on the basal surface of a porous filter, they were able to capture platelets perfused over the uncoated apical surface and induce platelet aggregation. Similar microthrombi were observed when endothelial cells were co-cultured on the apical surface. Confocal imaging shows podoplanin-expressing MSC extending processes into the EC layer, which could interact with circulating platelets. In both models, platelet aggregation induced by podoplanin-expressing MSC was inhibited by recombinant soluble CLEC-2. Thus, podoplanin may enhance the migratory capacity of tissue-resident MSC and enable novel interactions with cells expressing CLEC-2.


  • YraP Contributes to Cell Envelope Integrity and Virulence of Salmonella enterica Serovar Typhimurium

    by Faye C. Morris, Timothy J. Wells, Jack A. Bryant, Anna E. Schager, Yanina R. Sevastsyanovich, Derrick J. P. Squire, Jennifer Marshall, Georgia L. Isom, Jessica Rooke, Riyaz Maderbocus, et al.

    Mutations in σ E -regulated lipoproteins have previously been shown to impact bacterial viability under conditions of stress and during in vivo infection. YraP is conserved across a number of Gram-negative pathogens, including Neisseria meningitidis , where the homolog is a component of the Bexsero meningococcal group B vaccine.


  • Open Access

    Intestinal CD103+CD11b+ cDC2 Conventional Dendritic Cells Are Required for Primary CD4+ T and B Cell Responses to Soluble Flagellin

    by Adriana Flores-Langarica, Charlotte Cook, Katarzyna Müller Luda, Emma K. Persson, Jennifer L. Marshall, Nonantzin Beristain-Covarrubias, Juan Carlos Yam-Puc, Madelene Dahlgren, Jenny J. Persson, Satoshi Uematsu, et al.

    Systemic immunization with soluble flagellin (sFliC) from Salmonella Typhimurium induces mucosal responses, offering potential as an adjuvant platform for vaccines. Moreover, this engagement of mucosal immunity is necessary for optimal systemic immunity, demonstrating an interaction between these two semi-autonomous immune systems. Although TLR5 and CD103+CD11b+ cDC2 contribute to this process, the relationship between these is unclear in the early activation of CD4+ T cells and the development of antigen-specific B cell responses. In this work, we use TLR5-deficient mice and CD11c-cre.Irf4fl/fl mice (which have reduced numbers of cDC2, particularly intestinal CD103+CD11b+ cDCs), to address these points by studying the responses concurrently in the spleen and the mesenteric lymph nodes (MLN). We show that CD103+CD11b+ cDC2 respond rapidly and accumulate in the MLN after immunization with sFliC in a TLR5-dependent manner. Furthermore, we identify that whilst CD103+CD11b+ cDC2 are essential for the induction of primary T and B cell responses in the mucosa, they do not play such a central role for the induction of these responses in the spleen. Additionally, we show the involvement of CD103+CD11b+ cDC2 in the induction of Th2-associated responses. CD11c-cre.Irf4fl/fl mice showed a reduced primary FliC-specific Th2-associated IgG1 responses, but enhanced Th1-associated IgG2c responses. These data expand our current understanding of the mucosal immune responses promoted by sFliC and highlights the potential of this adjuvant for vaccine usage by taking advantage of the functionality of mucosal CD103+CD11b+ cDC2.


  • Open Access

    Pathologically distinct fibroblast subsets drive inflammation and tissue damage in arthritis

    by Adam P Croft, Joana Campos, Kathrin Jansen, Jason D Turner, Jennifer Marshall, Moustafa Attar, Loriane Savary, Harris Perlman, Francesca Barone, Helen M McGettrick, et al.

    SUMMARY: The identification of lymphocyte subsets with non-overlapping effector functions has been pivotal to the development of targeted therapies in immune mediated inflammatory diseases (IMIDs). However it remains unclear whether fibroblast subclasses with non-overlapping functions also exist and are responsible for the wide variety of tissue driven processes observed in IMIDs such as inflammation and damage. Here we identify and describe the biology of distinct subsets of fibroblasts responsible for mediating either inflammation or tissue damage in arthritis. We show that deletion of FAPα+ synovial cells suppressed both inflammation and bone erosions in murine models of resolving and persistent arthritis. Single cell transcriptional analysis identified two distinct fibroblast subsets: FAPα+ THY1+ immune effector fibroblasts located in the synovial sub-lining, and FAPα+ THY1- destructive fibroblasts restricted to the synovial lining. When adoptively transferred into the joint, FAP α+ THY1- fibroblasts selectively mediate bone and cartilage damage with little effect on inflammation whereas transfer of FAP α+ THY1+ fibroblasts resulted in a more severe and persistent inflammatory arthritis, with minimal effect on bone and cartilage. Our findings describing anatomically discrete, functionally distinct fibroblast subsets with non-overlapping functions have important implications for cell based therapies aimed at modulating inflammation and tissue damage.